Avantor, Inc. (AVTR) Stock Price & How to Invest

Avantor, Inc. is a global provider of high-purity materials, consumables, equipment, and specialized services used across biopharma, healthcare, education, government, and advanced technology markets. Founded in 1904 and headquartered in Radnor, Pennsylvania, the company sells everything from high-purity chemicals and reagents, lab supplies, and customized excipients to single-use assemblies, chromatography resins, and fluid handling systems. It reorganized around two reporting segments (Laboratory Solutions and a Bioscience and Medtech Products grouping), and a large share of its revenue is recurring consumables that customers reorder repeatedly, which gives the model a razor-and-blade quality tied to laboratory activity and biologic manufacturing volumes.

The investment picture as of October 2026 is still dominated by a turnaround, but one that has started to show up in results. Revenue slipped to roughly $6.55 billion in 2025, and trailing twelve-month revenue is about $6.56 billion. Q1 2026 beat expectations (adjusted EPS $0.17 vs $0.16), and Q2 2026 did so more clearly: revenue of about $1.69 billion was flat year over year but came in roughly 5% above analyst estimates, and adjusted EPS of $0.21 beat the $0.19 consensus. The stock rallied hard after the Q2 print and closed at $16.22 on October 16, 2026, up about 41% year to date and about 11% over one year, for a market value near $11 billion. Avantor still carries meaningful debt (about $3.7 billion against roughly $0.3 billion of cash), and its trailing GAAP net loss of about $578 million reflects a large write-down in Q3 2025, so the equity behaves like a leveraged recovery play: if organic growth and margins inflect, the valuation relative to larger tools peers leaves room for upside, but if end markets stay weak the balance sheet limits room for error.

Avantor's revenue was only flat in Q2 2026 and consensus still implies a roughly 5.5% year-over-year decline for Q3, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously. The company carries meaningful leverage (about $3.7 billion of debt and only about $0.3 billion of cash), which amplifies the downside if EBITDA disappoints and constrains flexibility. Trailing GAAP results show a net loss of about $578 million after a large Q3 2025 write-down, and the turnaround depends heavily on execution by a leadership team that only filled its CFO seat permanently in September 2026. After a rally of roughly 48% over three months, the share price now sits above the average analyst target, which leaves less cushion if the Q3 report disappoints. It also competes against much larger, better-capitalized peers such as Thermo Fisher, and its exposure to biopharma capex, academic funding cycles, and currency swings adds cyclicality. Any renewed destocking or funding cuts in life sciences would pressure results.

14 analysts publish price targets on AVTR, averaging $15.46 against a $16.42 price as of October 2026, or -5.8%. The published targets run from $13.00 to $19.00, a moderate spread, and the ratings split 2 buy, 13 hold, 1 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AVTR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Avantor, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Revival transformation program. Management launched a company-wide "Revival" program to cut costs, simplify the organization, and improve commercial execution. The most optimistic published target, $19.00, assumes this works close to its best case.

The case against. Avantor's revenue was only flat in Q2 2026 and consensus still implies a roughly 5.5% year-over-year decline for Q3, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously. The most pessimistic target, $13.00, is roughly what AVTR is worth if this bites instead.

Read the full bull and bear case on AVTR, including what would have to change to break either one. Walnut is not an investment adviser.

No. Avantor, Inc. (AVTR) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Avantor, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$6.56B
• Q2 2026 revenue: ~$1.69B (flat YoY, ~5% above estimates)
• Gross / operating margin: ~32% / ~7%
• Net income (TTM, GAAP): ~-$578M (Q3 2025 write-down)
• Forward P/E: ~18.5x
• Market cap: ~$11.0B
• Debt / cash: ~$3.7B / ~$0.3B

As of October 2026 Avantor trades at about 18.5x forward earnings and about 1.7x sales, a valuation that has re-rated sharply since the summer as two straight beats eased fears about the turnaround. It still sits at a discount to larger, higher-margin tools peers because of its slower growth and higher leverage. Figures are approximate and reference reported results through Q2 2026 and consensus estimates as of October 16, 2026.

Other names that sit close to AVTR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AVTR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AVTR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AVTR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Investors treat AVTR as a leveraged, recovery-stage bet on a stabilizing life sciences tools market, where execution on the Revival program matters as much as the underlying demand backdrop. After a roughly 48% three-month rally to about $16.22, the stock now sits above the average analyst target (~$15.46, a consensus Hold), so the Q3 report on October 28, 2026 carries more weight than usual.

Whether AVTR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AVTR a buy or a sell?, and where the stock could go from here in the AVTR stock forecast.

For income investors, whether AVTR pays a dividend and how the payout looks is covered in does AVTR pay a dividend? And to weigh AVTR against a peer, read the full side-by-side comparisons: AVTR vs TMO and AVTR vs DHR.